$SGMO
SANGAMO THERAPEUTICS, INC

2015 Q1 Form 10-Q Financial Statement

#000156459015002929 Filed on April 28, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q1
Revenue $13.49M $14.95M $8.116M
YoY Change 66.23% 117.67% 75.56%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.730M $4.330M $3.640M
YoY Change 29.95% 5.35% 9.97%
% of Gross Profit
Research & Development $14.98M $14.99M $12.08M
YoY Change 23.98% 39.05% 47.0%
% of Gross Profit
Depreciation & Amortization $147.0K $100.0K $123.0K
YoY Change 19.51% -50.0% -16.33%
% of Gross Profit
Operating Expenses $19.71M $19.42M $15.73M
YoY Change 25.34% 29.1% 36.42%
Operating Profit -$6.221M -$7.611M
YoY Change -18.26% 10.22%
Interest Expense $150.0K $150.0K $40.00K
YoY Change 275.0% 400.0% 100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.067M -$4.320M -$7.572M
YoY Change -19.88% -46.93% 9.9%
Income Tax -$748.0K $0.00
% Of Pretax Income
Net Earnings -$5.319M -$4.319M -$7.572M
YoY Change -29.75% -46.97% 9.98%
Net Earnings / Revenue -39.43% -28.89% -93.3%
Basic Earnings Per Share
Diluted Earnings Per Share -$76.79K -$62.96K -$119.8K
COMMON SHARES
Basic Shares Outstanding 69.17M 68.40M 62.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $225.7M $226.2M $213.4M
YoY Change 5.78% 63.44% 272.43%
Cash & Equivalents $25.26M $6.030M $126.8M
Short-Term Investments $200.5M $220.2M $86.60M
Other Short-Term Assets $1.000M $183.0K $349.0K
YoY Change 186.53% -4.19% 16.33%
Inventory
Prepaid Expenses $623.0K $370.0K
Receivables $6.600M $10.37M $5.360M
Other Receivables $400.0K $400.0K $300.0K
Total Short-Term Assets $203.9M $190.9M $220.2M
YoY Change -7.41% 96.23% 258.07%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000M $1.479M $1.410M
YoY Change 112.77% 5.19% -6.0%
Goodwill $1.585M $1.585M $1.585M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $29.80M $47.30M $30.40M
YoY Change -1.97% 22.22% 137.5%
Other Assets $157.0K $139.0K $0.00
YoY Change 247.5%
Total Long-Term Assets $34.61M $52.33M $35.29M
YoY Change -1.94% 20.13% 146.77%
TOTAL ASSETS
Total Short-Term Assets $203.9M $190.9M $220.2M
Total Long-Term Assets $34.61M $52.33M $35.29M
Total Assets $238.5M $243.2M $255.5M
YoY Change -6.65% 72.69% 237.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.800M $5.525M $6.100M
YoY Change 11.48% 82.83% 144.0%
Accrued Expenses $1.700M $3.400M $1.500M
YoY Change 13.33% -8.11% 36.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.97M $20.88M $16.41M
YoY Change 21.71% 106.12% 173.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.00M $14.90M $20.90M
YoY Change -47.37% 81.71% 151.81%
Total Long-Term Liabilities $11.00M $14.90M $20.90M
YoY Change -47.37% 81.71% 151.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.97M $20.88M $16.41M
Total Long-Term Liabilities $11.00M $14.90M $20.90M
Total Liabilities $31.02M $36.58M $38.08M
YoY Change -18.54% 91.23% 166.26%
SHAREHOLDERS EQUITY
Retained Earnings -$333.9M -$328.6M -$309.7M
YoY Change 7.8% 8.74%
Common Stock $541.3M $535.2M $678.0K
YoY Change 79742.48% 26.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $207.5M $206.6M $217.4M
YoY Change
Total Liabilities & Shareholders Equity $238.5M $243.2M $255.5M
YoY Change -6.65% 72.69% 237.07%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q1
OPERATING ACTIVITIES
Net Income -$5.319M -$4.319M -$7.572M
YoY Change -29.75% -46.97% 9.98%
Depreciation, Depletion And Amortization $147.0K $100.0K $123.0K
YoY Change 19.51% -50.0% -16.33%
Cash From Operating Activities -$2.400M -$2.700M $11.38M
YoY Change -121.09% 58.82% -241.92%
INVESTING ACTIVITIES
Capital Expenditures $1.084M $0.00 $126.0K
YoY Change 760.32% 85.29%
Acquisitions
YoY Change
Other Investing Activities $19.50M -$200.0K $4.000M
YoY Change 387.5% -99.71% -208.11%
Cash From Investing Activities $18.40M -$400.0K $3.887M
YoY Change 373.37% -99.42% -204.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.178M $7.585M
YoY Change -58.1%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.200M -2.100M 101.4M
YoY Change -96.84% -520.0% 4411.39%
NET CHANGE
Cash From Operating Activities -2.400M -2.700M 11.38M
Cash From Investing Activities 18.40M -400.0K 3.887M
Cash From Financing Activities 3.200M -2.100M 101.4M
Net Change In Cash 19.20M -5.200M 116.6M
YoY Change -83.54% -92.58% -1327.5%
FREE CASH FLOW
Cash From Operating Activities -$2.400M -$2.700M $11.38M
Capital Expenditures $1.084M $0.00 $126.0K
Free Cash Flow -$3.484M -$2.700M $11.25M
YoY Change -130.96% 58.82% -239.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1800000
CY2014Q4 us-gaap Liabilities
Liabilities
36579000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
690000
CY2015Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6806000
CY2015Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1703000
CY2015Q1 us-gaap Goodwill
Goodwill
1585000
CY2015Q1 us-gaap Assets
Assets
238505000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
19712000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6221000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7611000
CY2015Q1 sgmo Escrow Liability
EscrowLiability
275000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
11184000
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
11049000
CY2015Q1 us-gaap Liabilities
Liabilities
31017000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
695000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
540637000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333869000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
748000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19968000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
157000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14980000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4732000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3644000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
15727000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7563000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12083000
CY2015Q1 sgmo Collaboration Agreements
CollaborationAgreements
12671000
CY2014Q1 sgmo Collaboration Agreements
CollaborationAgreements
7568000
CY2015Q1 us-gaap Revenue From Grants
RevenueFromGrants
820000
CY2014Q1 us-gaap Revenue From Grants
RevenueFromGrants
548000
CY2015Q1 us-gaap Revenues
Revenues
13491000
CY2014Q1 us-gaap Revenues
Revenues
8116000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534518000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-328550000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
25000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
207488000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
206633000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
238505000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
243212000
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69497256
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69062394
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69497256
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69062394
CY2015Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
154000
CY2014Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
39000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6067000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7572000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-748000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5319000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7572000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69283000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63199000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5269000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
147000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-241000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-295000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2953000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1907000
CY2015Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1800000
CY2014Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
50000
CY2015Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1870000
CY2015Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-748000
CY2015Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-25000
CY2014Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
45000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3730000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2205000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-101000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
71000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2477000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1732000
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1150000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1723000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
34000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
18888000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2393000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11379000
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39423000
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16773000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
58955000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20786000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1084000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
126000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18448000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3887000
CY2014Q1 sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
93786000
CY2015Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3178000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7585000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3171000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
101371000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
19226000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
116637000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10186000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
126823000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
579000
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p></div>
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
17089000
CY2015Q1 us-gaap Marketable Securities
MarketableSecurities
200469000
CY2015Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
217558000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3182000
CY2014Q4 us-gaap Marketable Securities
MarketableSecurities
220192000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
223374000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1800000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1800000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1800000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
217533000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
223399000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
33000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
217558000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
223374000
CY2015Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2014 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2015Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2953000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1907000

Files In Submission

Name View Source Status
0001564590-15-002929-index-headers.html Edgar Link pending
0001564590-15-002929-index.html Edgar Link pending
0001564590-15-002929.txt Edgar Link pending
0001564590-15-002929-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201504281926018191269.jpg Edgar Link pending
g201504281926168661270.jpg Edgar Link pending
g201504281926445851271.jpg Edgar Link pending
g201504281926540221272.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20150331.htm Edgar Link pending
sgmo-20150331.xml Edgar Link completed
sgmo-20150331.xsd Edgar Link pending
sgmo-20150331_cal.xml Edgar Link unprocessable
sgmo-20150331_def.xml Edgar Link unprocessable
sgmo-20150331_lab.xml Edgar Link unprocessable
sgmo-20150331_pre.xml Edgar Link unprocessable
sgmo-ex101_20150331717.htm Edgar Link pending
sgmo-ex102_20150331594.htm Edgar Link pending
sgmo-ex311_201503319.htm Edgar Link pending
sgmo-ex312_201503316.htm Edgar Link pending
sgmo-ex321_2015033110.htm Edgar Link pending
Show.js Edgar Link pending